 Kerrie Moreau
Concepts (283)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Endothelium, Vascular | 21 | 2023 | 843 | 5.040 |
Why?
| | Menopause | 12 | 2022 | 271 | 4.840 |
Why?
| | Postmenopause | 16 | 2020 | 303 | 3.680 |
Why?
| | Vascular Stiffness | 11 | 2023 | 407 | 3.160 |
Why?
| | Aging | 17 | 2023 | 1620 | 2.740 |
Why?
| | Estrogens | 12 | 2023 | 312 | 2.330 |
Why?
| | Estradiol | 7 | 2020 | 455 | 2.130 |
Why?
| | Brachial Artery | 13 | 2020 | 176 | 2.010 |
Why?
| | Carotid Arteries | 12 | 2021 | 180 | 1.940 |
Why?
| | Vasodilation | 12 | 2020 | 415 | 1.940 |
Why?
| | Cardiovascular Diseases | 15 | 2023 | 1727 | 1.930 |
Why?
| | Testosterone | 4 | 2022 | 343 | 1.890 |
Why?
| | Vascular Diseases | 4 | 2022 | 230 | 1.870 |
Why?
| | Oxidative Stress | 12 | 2022 | 1084 | 1.740 |
Why?
| | Exercise | 14 | 2023 | 1644 | 1.720 |
Why?
| | Gonadal Steroid Hormones | 3 | 2019 | 124 | 1.230 |
Why?
| | Nitric Oxide Synthase Type III | 4 | 2022 | 184 | 1.130 |
Why?
| | Body Composition | 8 | 2022 | 592 | 1.070 |
Why?
| | Ascorbic Acid | 5 | 2016 | 110 | 0.990 |
Why?
| | Cardiovascular Physiological Phenomena | 3 | 2021 | 40 | 0.990 |
Why?
| | Pulse Wave Analysis | 4 | 2023 | 207 | 0.960 |
Why?
| | Sex Characteristics | 5 | 2023 | 640 | 0.930 |
Why?
| | Middle Cerebral Artery | 1 | 2023 | 37 | 0.880 |
Why?
| | Aged | 33 | 2023 | 19094 | 0.870 |
Why?
| | Perimenopause | 3 | 2022 | 61 | 0.820 |
Why?
| | Compliance | 6 | 2018 | 46 | 0.820 |
Why?
| | Antioxidants | 4 | 2022 | 530 | 0.810 |
Why?
| | Female | 58 | 2023 | 59507 | 0.810 |
Why?
| | Baroreflex | 1 | 2022 | 54 | 0.790 |
Why?
| | Muscle, Skeletal | 4 | 2020 | 1472 | 0.760 |
Why?
| | Middle Aged | 38 | 2023 | 26757 | 0.740 |
Why?
| | Femoral Artery | 4 | 2006 | 167 | 0.730 |
Why?
| | Blood Vessels | 2 | 2019 | 180 | 0.710 |
Why?
| | Hyperemia | 1 | 2020 | 45 | 0.700 |
Why?
| | Estrogen Replacement Therapy | 5 | 2013 | 116 | 0.700 |
Why?
| | Polycystic Ovary Syndrome | 2 | 2019 | 141 | 0.680 |
Why?
| | Humans | 71 | 2023 | 114756 | 0.680 |
Why?
| | Homocysteine | 2 | 2019 | 136 | 0.660 |
Why?
| | Physical Endurance | 5 | 2013 | 231 | 0.660 |
Why?
| | Premenopause | 6 | 2020 | 107 | 0.630 |
Why?
| | Cysteine | 1 | 2019 | 171 | 0.600 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 6 | 2021 | 916 | 0.590 |
Why?
| | Muscle Proteins | 1 | 2019 | 210 | 0.570 |
Why?
| | Adult | 31 | 2023 | 30548 | 0.570 |
Why?
| | Bone Density | 1 | 2021 | 432 | 0.570 |
Why?
| | Ovary | 1 | 2018 | 191 | 0.560 |
Why?
| | Cross-Sectional Studies | 10 | 2023 | 4409 | 0.560 |
Why?
| | Regional Blood Flow | 4 | 2020 | 424 | 0.560 |
Why?
| | Arginine | 1 | 2017 | 236 | 0.530 |
Why?
| | Ventricular Function, Left | 3 | 2023 | 467 | 0.500 |
Why?
| | Nitric Oxide | 4 | 2023 | 824 | 0.460 |
Why?
| | Male | 35 | 2023 | 55579 | 0.460 |
Why?
| | Estrogen Receptor alpha | 2 | 2019 | 121 | 0.460 |
Why?
| | Ultrasonography | 6 | 2018 | 629 | 0.430 |
Why?
| | Receptors, Tumor Necrosis Factor | 1 | 2013 | 139 | 0.420 |
Why?
| | Health | 1 | 2012 | 74 | 0.400 |
Why?
| | Hysterectomy | 1 | 2012 | 106 | 0.390 |
Why?
| | Young Adult | 11 | 2022 | 10463 | 0.390 |
Why?
| | Cognitive Dysfunction | 3 | 2021 | 284 | 0.370 |
Why?
| | Renal Insufficiency, Chronic | 3 | 2023 | 486 | 0.370 |
Why?
| | Blood Pressure | 4 | 2023 | 1530 | 0.370 |
Why?
| | Depression | 1 | 2018 | 1133 | 0.350 |
Why?
| | Vasodilator Agents | 1 | 2012 | 303 | 0.340 |
Why?
| | Follicle Stimulating Hormone | 2 | 2021 | 216 | 0.330 |
Why?
| | Immunoglobulin G | 1 | 2013 | 774 | 0.330 |
Why?
| | Smoking | 4 | 2022 | 1384 | 0.330 |
Why?
| | Tunica Intima | 2 | 2006 | 78 | 0.320 |
Why?
| | Quality of Life | 2 | 2021 | 2358 | 0.320 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2013 | 1134 | 0.310 |
Why?
| | Transgender Persons | 2 | 2021 | 134 | 0.300 |
Why?
| | Biomarkers | 5 | 2020 | 3416 | 0.280 |
Why?
| | Ventricular Dysfunction, Left | 2 | 2023 | 359 | 0.270 |
Why?
| | Plethysmography | 2 | 2022 | 104 | 0.260 |
Why?
| | Vasoconstriction | 1 | 2006 | 177 | 0.250 |
Why?
| | Menstrual Cycle | 2 | 2020 | 108 | 0.250 |
Why?
| | Oxygen Consumption | 5 | 2016 | 588 | 0.240 |
Why?
| | Inflammation | 4 | 2023 | 2481 | 0.230 |
Why?
| | Absorptiometry, Photon | 3 | 2021 | 224 | 0.230 |
Why?
| | Women's Health | 2 | 2019 | 271 | 0.230 |
Why?
| | Adolescent | 13 | 2022 | 17808 | 0.220 |
Why?
| | Diastole | 3 | 2023 | 131 | 0.220 |
Why?
| | Elastin | 1 | 2023 | 78 | 0.210 |
Why?
| | Peroxynitrous Acid | 1 | 2022 | 11 | 0.210 |
Why?
| | Blood Flow Velocity | 2 | 2022 | 387 | 0.200 |
Why?
| | Exercise Therapy | 2 | 2022 | 351 | 0.200 |
Why?
| | Sex Factors | 4 | 2022 | 1717 | 0.190 |
Why?
| | Gene Expression Regulation, Enzymologic | 2 | 2017 | 271 | 0.190 |
Why?
| | Ultrasonography, Doppler | 1 | 2022 | 105 | 0.190 |
Why?
| | Progesterone | 1 | 2002 | 232 | 0.190 |
Why?
| | Transsexualism | 1 | 2021 | 17 | 0.190 |
Why?
| | Cardiology | 1 | 2023 | 259 | 0.190 |
Why?
| | Leg | 1 | 2002 | 225 | 0.180 |
Why?
| | Follicular Phase | 1 | 2020 | 36 | 0.180 |
Why?
| | Heart Rate | 2 | 2022 | 704 | 0.180 |
Why?
| | Insulin Resistance | 2 | 2020 | 1072 | 0.180 |
Why?
| | Carotid Artery Diseases | 1 | 2020 | 57 | 0.170 |
Why?
| | Cardiomyopathies | 1 | 2023 | 298 | 0.170 |
Why?
| | Body Mass Index | 4 | 2020 | 1958 | 0.160 |
Why?
| | Receptor, Endothelin B | 1 | 2019 | 51 | 0.160 |
Why?
| | Smokers | 1 | 2019 | 128 | 0.160 |
Why?
| | Taurine | 1 | 2019 | 41 | 0.160 |
Why?
| | Cystathionine beta-Synthase | 1 | 2019 | 59 | 0.160 |
Why?
| | Interleukin-6 | 1 | 2022 | 675 | 0.150 |
Why?
| | Homocystinuria | 1 | 2019 | 62 | 0.150 |
Why?
| | Sports | 1 | 2000 | 187 | 0.150 |
Why?
| | Sleep Apnea, Obstructive | 1 | 2021 | 200 | 0.150 |
Why?
| | Biomedical Research | 1 | 2023 | 585 | 0.150 |
Why?
| | Risk Factors | 6 | 2021 | 8627 | 0.150 |
Why?
| | Androgens | 1 | 2019 | 167 | 0.150 |
Why?
| | Lactic Acid | 1 | 1999 | 275 | 0.150 |
Why?
| | Apyrase | 1 | 2017 | 14 | 0.140 |
Why?
| | Neuropsychological Tests | 2 | 2021 | 926 | 0.140 |
Why?
| | Metabolism | 1 | 2017 | 35 | 0.140 |
Why?
| | Oxidation-Reduction | 1 | 2020 | 927 | 0.140 |
Why?
| | Cholecalciferol | 1 | 2017 | 47 | 0.140 |
Why?
| | Calcitriol | 1 | 2017 | 53 | 0.140 |
Why?
| | Nutritional Status | 1 | 2019 | 286 | 0.140 |
Why?
| | Venoms | 1 | 2016 | 30 | 0.140 |
Why?
| | Attention | 1 | 2019 | 394 | 0.140 |
Why?
| | Diabetic Cardiomyopathies | 1 | 2016 | 34 | 0.130 |
Why?
| | Cognition | 2 | 2021 | 989 | 0.130 |
Why?
| | Affect | 1 | 2018 | 246 | 0.130 |
Why?
| | Peripheral Arterial Disease | 1 | 2022 | 380 | 0.130 |
Why?
| | Mitral Valve | 1 | 2016 | 87 | 0.130 |
Why?
| | Analysis of Variance | 1 | 2018 | 1226 | 0.130 |
Why?
| | Echocardiography | 2 | 2016 | 554 | 0.120 |
Why?
| | Heart Ventricles | 2 | 2016 | 709 | 0.120 |
Why?
| | Antigens, CD | 1 | 2017 | 443 | 0.120 |
Why?
| | Diabetic Angiopathies | 1 | 2016 | 244 | 0.120 |
Why?
| | Receptors, Estrogen | 1 | 2017 | 372 | 0.120 |
Why?
| | Glomerular Filtration Rate | 1 | 2017 | 604 | 0.120 |
Why?
| | Psychometrics | 1 | 2017 | 607 | 0.110 |
Why?
| | Dietary Supplements | 1 | 2017 | 460 | 0.110 |
Why?
| | Etanercept | 1 | 2013 | 51 | 0.110 |
Why?
| | Venous Thromboembolism | 1 | 2017 | 231 | 0.110 |
Why?
| | Administration, Cutaneous | 1 | 2013 | 117 | 0.110 |
Why?
| | Adaptation, Physiological | 1 | 2017 | 483 | 0.110 |
Why?
| | Healthy Volunteers | 1 | 2013 | 197 | 0.100 |
Why?
| | Upper Extremity | 2 | 2013 | 84 | 0.100 |
Why?
| | Hormone Replacement Therapy | 1 | 2013 | 77 | 0.100 |
Why?
| | Ovariectomy | 1 | 2012 | 116 | 0.100 |
Why?
| | Brain | 1 | 2023 | 2374 | 0.100 |
Why?
| | Receptors, CCR5 | 1 | 2012 | 54 | 0.100 |
Why?
| | Cervix Uteri | 1 | 2012 | 45 | 0.100 |
Why?
| | Diet | 1 | 2019 | 1080 | 0.100 |
Why?
| | Time Factors | 3 | 2019 | 6124 | 0.100 |
Why?
| | Heart | 1 | 2015 | 609 | 0.100 |
Why?
| | Animals | 4 | 2023 | 31761 | 0.100 |
Why?
| | Fluorescent Antibody Technique | 2 | 2009 | 396 | 0.100 |
Why?
| | Peptides | 1 | 2016 | 848 | 0.090 |
Why?
| | Administration, Oral | 1 | 2013 | 731 | 0.090 |
Why?
| | Resistance Training | 1 | 2013 | 113 | 0.090 |
Why?
| | Double-Blind Method | 3 | 2023 | 1662 | 0.090 |
Why?
| | Surveys and Questionnaires | 2 | 2021 | 4625 | 0.090 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2013 | 299 | 0.090 |
Why?
| | Kidney | 1 | 2017 | 1184 | 0.090 |
Why?
| | Pediatric Obesity | 1 | 2017 | 489 | 0.090 |
Why?
| | Gene Expression Regulation | 1 | 2019 | 2321 | 0.090 |
Why?
| | Case-Control Studies | 3 | 2020 | 3005 | 0.090 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2017 | 1892 | 0.080 |
Why?
| | Retrospective Studies | 3 | 2022 | 12515 | 0.080 |
Why?
| | Hypoglycemic Agents | 1 | 2016 | 1009 | 0.080 |
Why?
| | Walking | 2 | 2015 | 422 | 0.080 |
Why?
| | Aged, 80 and over | 3 | 2012 | 6350 | 0.080 |
Why?
| | NADPH Oxidases | 1 | 2007 | 120 | 0.070 |
Why?
| | HIV-1 | 1 | 2012 | 768 | 0.070 |
Why?
| | Risk Assessment | 3 | 2021 | 2973 | 0.070 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2012 | 965 | 0.070 |
Why?
| | Models, Theoretical | 2 | 2000 | 516 | 0.070 |
Why?
| | Clothing | 1 | 2006 | 19 | 0.070 |
Why?
| | Prospective Studies | 3 | 2023 | 6217 | 0.060 |
Why?
| | Disease Susceptibility | 2 | 2021 | 316 | 0.060 |
Why?
| | Waist-Hip Ratio | 1 | 2005 | 30 | 0.060 |
Why?
| | Vascular Resistance | 2 | 2006 | 337 | 0.060 |
Why?
| | DNA Methylation | 1 | 2009 | 496 | 0.060 |
Why?
| | Activities of Daily Living | 2 | 2021 | 350 | 0.060 |
Why?
| | Data Collection | 1 | 2008 | 622 | 0.060 |
Why?
| | Exercise Tolerance | 2 | 2016 | 213 | 0.060 |
Why?
| | Elasticity | 1 | 2005 | 189 | 0.060 |
Why?
| | Executive Function | 2 | 2020 | 379 | 0.060 |
Why?
| | Norepinephrine | 1 | 2005 | 200 | 0.060 |
Why?
| | Endothelial Cells | 1 | 2009 | 681 | 0.060 |
Why?
| | Inflammation Mediators | 2 | 2017 | 476 | 0.060 |
Why?
| | Cholesterol, LDL | 1 | 2005 | 307 | 0.050 |
Why?
| | Proteins | 1 | 2009 | 912 | 0.050 |
Why?
| | Bicarbonates | 1 | 2023 | 41 | 0.050 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2016 | 2097 | 0.050 |
Why?
| | Sodium Bicarbonate | 1 | 2023 | 40 | 0.050 |
Why?
| | Prognosis | 2 | 2021 | 3334 | 0.050 |
Why?
| | Overweight | 1 | 2007 | 471 | 0.050 |
Why?
| | Age Factors | 2 | 2020 | 2890 | 0.050 |
Why?
| | Cohort Studies | 1 | 2012 | 4901 | 0.050 |
Why?
| | Matrix Metalloproteinase 9 | 1 | 2023 | 119 | 0.050 |
Why?
| | Cardiac Output | 1 | 2002 | 142 | 0.050 |
Why?
| | Physical Education and Training | 1 | 2002 | 62 | 0.050 |
Why?
| | Cardiovascular System | 1 | 2023 | 125 | 0.050 |
Why?
| | Ankle Brachial Index | 1 | 2022 | 30 | 0.050 |
Why?
| | Follow-Up Studies | 3 | 2020 | 4420 | 0.050 |
Why?
| | Sympathetic Nervous System | 1 | 2002 | 171 | 0.050 |
Why?
| | Carotid Artery, Common | 1 | 2021 | 29 | 0.050 |
Why?
| | Triglycerides | 1 | 2023 | 470 | 0.050 |
Why?
| | Aorta | 1 | 2023 | 386 | 0.040 |
Why?
| | Arteries | 2 | 2016 | 247 | 0.040 |
Why?
| | Fibrinolytic Agents | 1 | 2022 | 233 | 0.040 |
Why?
| | Severity of Illness Index | 2 | 2019 | 2539 | 0.040 |
Why?
| | Reference Values | 1 | 2000 | 742 | 0.040 |
Why?
| | Lipids | 2 | 2017 | 582 | 0.040 |
Why?
| | Stress, Physiological | 1 | 2021 | 379 | 0.040 |
Why?
| | Respiratory Function Tests | 1 | 2019 | 524 | 0.040 |
Why?
| | Myocardium | 1 | 2023 | 908 | 0.040 |
Why?
| | HIV Infections | 1 | 2012 | 2469 | 0.040 |
Why?
| | Colorado | 2 | 2017 | 4086 | 0.040 |
Why?
| | Self-Assessment | 1 | 2017 | 61 | 0.040 |
Why?
| | Carotid Intima-Media Thickness | 1 | 2017 | 65 | 0.030 |
Why?
| | Energy Metabolism | 1 | 2022 | 729 | 0.030 |
Why?
| | Treatment Outcome | 2 | 2022 | 9089 | 0.030 |
Why?
| | Culture | 1 | 2017 | 124 | 0.030 |
Why?
| | Memory Disorders | 1 | 2017 | 155 | 0.030 |
Why?
| | Adipose Tissue | 1 | 2020 | 539 | 0.030 |
Why?
| | Glucose Clamp Technique | 1 | 2017 | 181 | 0.030 |
Why?
| | Metabolic Diseases | 1 | 2017 | 99 | 0.030 |
Why?
| | Sensitivity and Specificity | 1 | 2000 | 1691 | 0.030 |
Why?
| | Reaction Time | 1 | 2017 | 376 | 0.030 |
Why?
| | Glucagon-Like Peptide 1 | 1 | 2016 | 101 | 0.030 |
Why?
| | Alternative Splicing | 1 | 2017 | 188 | 0.030 |
Why?
| | Pilot Projects | 1 | 2020 | 1370 | 0.030 |
Why?
| | Echocardiography, Doppler | 1 | 2015 | 92 | 0.030 |
Why?
| | HEK293 Cells | 1 | 2017 | 593 | 0.030 |
Why?
| | Obesity | 1 | 2007 | 2513 | 0.030 |
Why?
| | Vitamin D | 1 | 2017 | 341 | 0.030 |
Why?
| | Diabetes Mellitus | 1 | 2022 | 904 | 0.030 |
Why?
| | Hypertension | 1 | 2022 | 1059 | 0.030 |
Why?
| | Mice, Inbred C57BL | 1 | 2023 | 4710 | 0.030 |
Why?
| | Recovery of Function | 1 | 2017 | 572 | 0.030 |
Why?
| | Stress, Psychological | 1 | 2021 | 944 | 0.030 |
Why?
| | Ventricular Function, Right | 1 | 2015 | 251 | 0.030 |
Why?
| | Hospitals, Pediatric | 1 | 2017 | 479 | 0.030 |
Why?
| | Lost to Follow-Up | 1 | 2013 | 22 | 0.030 |
Why?
| | Sex Hormone-Binding Globulin | 1 | 2013 | 48 | 0.030 |
Why?
| | Stroke Volume | 1 | 2015 | 508 | 0.030 |
Why?
| | Exercise Test | 1 | 2015 | 544 | 0.030 |
Why?
| | Patient Dropouts | 1 | 2013 | 66 | 0.030 |
Why?
| | ADP-ribosyl Cyclase 1 | 1 | 2012 | 35 | 0.030 |
Why?
| | Genotype | 1 | 2017 | 1774 | 0.020 |
Why?
| | Geriatric Assessment | 1 | 2013 | 176 | 0.020 |
Why?
| | Statistics, Nonparametric | 1 | 2012 | 386 | 0.020 |
Why?
| | HLA-DR Antigens | 1 | 2012 | 220 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2015 | 1796 | 0.020 |
Why?
| | Muscle Strength | 1 | 2013 | 270 | 0.020 |
Why?
| | Combined Modality Therapy | 1 | 2013 | 1122 | 0.020 |
Why?
| | Xanthine Oxidase | 1 | 2009 | 71 | 0.020 |
Why?
| | Veins | 1 | 2009 | 55 | 0.020 |
Why?
| | Child | 2 | 2019 | 18352 | 0.020 |
Why?
| | Polymerase Chain Reaction | 1 | 2012 | 994 | 0.020 |
Why?
| | Patient Compliance | 1 | 2013 | 525 | 0.020 |
Why?
| | Transcription Factor RelA | 1 | 2009 | 83 | 0.020 |
Why?
| | Serine | 1 | 2009 | 126 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2013 | 1846 | 0.020 |
Why?
| | Genetic Predisposition to Disease | 1 | 2017 | 2099 | 0.020 |
Why?
| | Tyrosine | 1 | 2009 | 215 | 0.020 |
Why?
| | Blood Glucose | 1 | 2017 | 1821 | 0.020 |
Why?
| | Microscopy, Fluorescence | 1 | 2009 | 398 | 0.020 |
Why?
| | Superoxide Dismutase | 1 | 2009 | 305 | 0.020 |
Why?
| | Reference Standards | 1 | 2008 | 159 | 0.020 |
Why?
| | Lung | 1 | 2019 | 3546 | 0.020 |
Why?
| | Insulin | 1 | 2017 | 2079 | 0.020 |
Why?
| | Monitoring, Ambulatory | 1 | 2008 | 81 | 0.020 |
Why?
| | Mice | 1 | 2023 | 14916 | 0.020 |
Why?
| | Linear Models | 1 | 2009 | 770 | 0.020 |
Why?
| | Sodium, Dietary | 1 | 2006 | 36 | 0.020 |
Why?
| | DNA | 1 | 2012 | 1351 | 0.020 |
Why?
| | Phosphorylation | 1 | 2009 | 1571 | 0.020 |
Why?
| | Body Weight | 1 | 2008 | 869 | 0.010 |
Why?
| | Regression Analysis | 1 | 2006 | 946 | 0.010 |
Why?
| | United States | 1 | 2019 | 12176 | 0.010 |
Why?
| | Hypertrophy, Left Ventricular | 1 | 2003 | 102 | 0.010 |
Why?
| | Pulse | 1 | 1980 | 27 | 0.010 |
Why?
| | Ear | 1 | 1980 | 32 | 0.010 |
Why?
| | Reproducibility of Results | 1 | 2006 | 2763 | 0.010 |
Why?
| | Hemodynamics | 1 | 2003 | 1013 | 0.010 |
Why?
| | Transducers | 1 | 1980 | 25 | 0.000 |
Why?
| | Systole | 1 | 1980 | 171 | 0.000 |
Why?
| | Arrhythmias, Cardiac | 1 | 1980 | 278 | 0.000 |
Why?
|
|
Moreau's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|